<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131094">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01871077</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH156-0612/I</org_study_id>
    <nct_id>NCT01871077</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.</brief_title>
  <official_title>Phase I Clinical Trial to Assess the Safety and Tolerability of the Ophthalmic Solution PRO-156 Over the Ocular Surface of Ophthalmologically Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability of the ophthalmic solution
      PRO-156 over the ocular surface of ophthalmologically healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability
      of the ophthalmic solution PRO-143 over the ocular surface of ophthalmologically healthy
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of PRO-156 ohthalmic solution</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate safety of PRO-156 in the ocular surface by the prescence of ocular signs and symptoms,visual acuity (VA), intraocular pressure (IOP), corneal and conjunctival staining (Fluoroscein and lissamine green staining).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PRO-156 Ophthalmic Solution</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of ocular symptoms (redness, burning, foreign body sensation, itching, eye discharge and tearing)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PRO-156</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-156</intervention_name>
    <description>Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.</description>
    <arm_group_label>PRO-156</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female.

          -  Age between 18 and 40 years old at screening visit.

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient with one blind eye.

          -  Any ocular or systemic condition.

          -  Visual acuity of 20/100 in any eye.

          -  Use of ocular or systemics medications.

          -  Contraindications or sensitivity to any component of the study treatment.

          -  Contact lens users.

          -  Ocular surgery within the past 3 months..

          -  Pregnant, nursing or childbearing potential women who were not using effective
             contraception.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Casillas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent Clinical Research Center</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
